Table 3. Treatment and outcomes.

Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; ICU, intensive care unit.

p values were calculated by the chi-squared test or Fisher’s exact test for categorical variables.

* Expressed in frequency (%).

Treatment and outcomes	Total (134)	ICU (n = 45)	Non-ICU (89)	p value
Complications*
ARDS	13 (9.7%)	13 (28.9%)	0	< .001
AKI	8 (6%)	8 (17.8%)	0	< .001
Extrarenal epuration	8 (6%)	8 (17.8%)	0	< .001
Arrythmia	3 (2.2%)	3 (6.6%)	0	.029
Pneumothorax	2 (1.5%)	2 (4.4%)	0	.094
Thromboembolic events	4 (2.9%)	4 (8.8%)	0	.012
Septic shock	1 (0.01%)	1 (2.2%)	0	.303
Death	14 (10.4%)	14 (31.1%)	0	< .001
Causes of death*
ARDS + AKI	8 (5.9%)	8 (17.8%)	0	< .001
ARDS alone	4 (3%)	4 (8.9%)	0	.012
Septic shock	1 (0.7%)	1 (2.2%)	0	.303
Decompensated cirrhosis	1 (0.7%)	1 (2.2%)	0	.198
Treatments*
Hydroxychloroquine	127 (95%)	43 (95.5%)	84 (96.6%)	1.000
Azithromycin	127 (95%)	43 (95%)	84 (94.4%)	1.000
Lopinavir + ritonavir	11 (8.2%)	11 (24.4%)	0	.001
Tocilizumab	5 (3.7%)	5 (11.1%)	0	.004
Cephalosporin third generation	24 (17.9%)	22 (48.9%)	2 (2.2%)	< .001
Quinolones	21 (15.7%)	20 (44.4%)	1 (1.1%)	< .001
Aminosides	9 (6.7%)	9 (20%)	0	< .001
Carbapenem	8 (6%)	8 (17.8%)	0	< .001
Corticosteroids	14 (10.4%)	14 (31.1%)	0	< .001
Low molecular weight heparin	111 (82%)	43 (95.6%)	68 (76.4%)	.005
Catecholamines	13 (9.7%)	13 (28.9%)	0	< .001
Non-rebreather mask	23 (17.2%)	23 (51.1%)	0	< .001
Noninvasive ventilation	8 (5.9%)	8 (17.8%)	0	< .001
Invasive mechanical ventilation	14 (10.4%)	14 (31.1%)	0	< .001